Kathy D. Miller, MD: Hi. I am Kathy Miller, Associate Professor of Medicine at the Indiana University School of Medicine in Indianapolis, Indiana. Welcome to Medscape Oncology Insights on Breast Cancer, coming to you from the 2014 annual meeting of the American Society of Clinical Oncology (ASCO®). Joining me today is Dr. Karen Gelmon, Professor of Medicine at the University of British Columbia and Head of the Division of Medical Oncology of the British Columbia Cancer Agency in Vancouver. Welcome, Karen.
Karen A. Gelmon, MD: Thank you. It's nice to be here.
Surprising Results: The ALTTO Trial
Dr. Miller: Two breast cancer abstracts were presented at the plenary session this year. Let's start at the top and talk about the largest study, maybe one of the largest studies in history -- the ALTTO trial.[1] We have been awaiting these results for a long time. What have we learned?
Dr. Gelmon: The ALTTO trial is very interesting. More than 8000 women were randomly assigned, so it was a huge study. We had NeoALTTO[2]in which we looked at the combination of lapatinib and trastuzumab, and it showed that the combination was superior, so we have all been waiting for the ALTTO study.
Mastectomy May Not Be Necessary for Young Breast Cancer Patients
New Image-Based Risk Model Helps Predict Future Breast Cancers
Patient Simulation: A 45-Year-Old Woman With High-Risk Early HR+/HER2- Breast Cancer
Patient Simulation: A 63-Year-Old Woman With PIK3CA Breast Cancer and Unilateral Rib Pain
COMMENTARY
Results Flat in ALTTO Breast Cancer Trial
Kathy D. Miller, MD; Karen A. Gelmon, MD
DisclosuresJune 06, 2014
Kathy D. Miller, MD: Hi. I am Kathy Miller, Associate Professor of Medicine at the Indiana University School of Medicine in Indianapolis, Indiana. Welcome to Medscape Oncology Insights on Breast Cancer, coming to you from the 2014 annual meeting of the American Society of Clinical Oncology (ASCO®). Joining me today is Dr. Karen Gelmon, Professor of Medicine at the University of British Columbia and Head of the Division of Medical Oncology of the British Columbia Cancer Agency in Vancouver. Welcome, Karen.
Karen A. Gelmon, MD: Thank you. It's nice to be here.
Surprising Results: The ALTTO Trial
Dr. Miller: Two breast cancer abstracts were presented at the plenary session this year. Let's start at the top and talk about the largest study, maybe one of the largest studies in history -- the ALTTO trial.[1] We have been awaiting these results for a long time. What have we learned?
Dr. Gelmon: The ALTTO trial is very interesting. More than 8000 women were randomly assigned, so it was a huge study. We had NeoALTTO[2]in which we looked at the combination of lapatinib and trastuzumab, and it showed that the combination was superior, so we have all been waiting for the ALTTO study.
Medscape Oncology © 2014 WebMD, LLC
Cite this: Results Flat in ALTTO Breast Cancer Trial - Medscape - Jun 06, 2014.
Tables
References
Authors and Disclosures
Authors and Disclosures
Co-Authors
Kathy D. Miller, MD
Associate Professor; Co-Director, Breast Cancer Team, Indiana University Simon Cancer Center, Indianapolis, Indiana
Disclosure: Kathy D. Miller, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Clovis; Nektar; Antigen Express
Received a research grant from: Research grants to Indiana University; salary not contingent on study results. Sponsors include Syndax, Genentech/Roche, Merrimack, Geron, Imclone, Taiho, Macrogenics, Seattle Genetics
Karen A. Gelmon, MD
Professor, Department of Medicine, University of British Columbia; Head, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia
Disclosure: Karen A. Gelmon, MD, has disclosed no relevant financial relationships.